Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±¾Ï¿¡¼­ Á÷Àå¼öÁö°Ë»ç, Ç÷û Àü¸³¼±Æ¯ÀÌÇ׿øÄ¡ ¹× °æÁ÷Àå ÃÊÀ½ÆÄ°Ë»çÀÇ Áø´ÜÀû °¡Ä¡¿¡ ´ëÇÑ ºñ±³¿¬±¸ Comparative Study on Diagnostic Value of Digital Rectal Examination, Serum Prostate Specific Antigen and Transrectal Ultrasound in Prostate Cancer

´ëÇѺñ´¢±â°úÇÐȸÁö 1997³â 38±Ç 12È£ p.1325 ~ 1332
¼Ò¼Ó »ó¼¼Á¤º¸
À¯¼ºÇÏ/Seong Ha Yoo ±è¼±Áø/½Å±â¿ë/ÃÖµµ¿¬/¹ÚÇØ¿µ/ÀÌÃá¿ë/¿ì¿µ³²/±èµ¿ÇÑ/Sun Jin Kim/Ki Yong Shin/Do Yeon Choi/Hae Young park/Tchun Yong Lee/Young Nam Woo/Dong Han Kim

Abstract

°á·Ð
ù°, ¹è´¢Áõ»óÀ» ÁÖ¼Ò·Î ³»¿øÇÑ È¯ÀÚ±ºÀ» ´ë»óÀ¸·ÎÇÑ °ËÁø¿¡¼­ Àü¸³¼±¾Ï¿¡ ´ëÇÑ °æÁ÷Àå
¼öÁö °Ë»ç, °æÁ÷Àå Ç÷û PSA (2.5 ng/§¢<)ÃøÁ¤¹ýÀÇ ¹Î°¨µµ ¹× ƯÀ̵µ´Â °¢°¢ 90%¿Í 40%,
81%¿Í 42.9%, 100%¿Í 14.3% ¿´À¸¸ç ¾Ï°ËÃâÀ²Àº 47.5%, 48.1% ¹× 34.1%À̾ú´Ù.
µÑ°, Ç÷û PSA°Ë»ç¹ýÀº ¹Î°¨µµ¿¡ ºñÇÏ¿© ƯÀ̵µ°¡ ³Ê¹« ³·¾Æ Áý´Ü °ËÁø¿¡¼­ÀÇ ±âº» °Ë
»ç·Î¼­ÀÇ Áø´ÜÀû °¡Ä¡´Â ³·¾ÒÀ¸¸ç ÀÌÀÇ °³¼±À» À§ÇÏ¿©´Â °Ë»ç¹ý, °Ë»ç±ºÀÇ ³ªÀÌ, °ú°Åº´·Â¿¡
µû¸¥ Á¤»ó¹üÀ§ °ªÀÇ ¼³Á¤, PSA ¹Ðµµ, PSA ¼Óµµ µîÀÇ ÀÓ»óÀû °¡Ä¡¿¡ °üÇÑ Àç°ËÁõ µîÀÌ ÇÊ
¿äÇÒ °ÍÀ¸·Î »ç·áµÈ´Ù.
¼Â°, ´ÜÀÏ °Ë»ç¹ý¿¡ ºñÇÏ¿© DRE, PSA TRUS ¹× TRUS À¯µµÇÏ Á¶Á÷°Ë»ç¹ýÀ» ÇÔ²² ½ÃÇà
Çϸé Àü¸³¼±¾ÏÀÇ °ËÃâÀ²À» ³ôÀÏ ¼ö ÀÖÀ¸³ª Áý´Ü °ËÁøµîÀÇ ´Ù¼ö¸¦ ´ë»óÀ¸·Î ÇÑ ½ÃÇàÀ» Çϱâ
À§ÇÏ¿©´Â Ä« °Ë»ç¹ýÀÇ ¹Î°¨µµ¿Í ƯÀ̵µ¸¦ ³ôÀ̱â À§ÇÑ ³ë·Â°ú Á»´õ ¸¹Àº ¼ö¿Í °èÃþÀ» ´ë»ó
À¸·Î °¢ °Ë»ç¹ýÀÇ ºñ¿ë-È¿°ú µîÀ» Æ÷ÇÔÇÑ Áø´ÜÀû °¡Ä¡¿¡ ´ëÇÑ Æò°¡°¡ ¼±ÇàµÇ¾î¾ß ÇÒ °ÍÀ¸
·Î »ç·áµÈ´Ù.
#ÃÊ·Ï#
We analysed 101 patients with voiding symptoms of suggestive prostatism to evaluate
the diagnostic values of digital rectal examination (DRE), serum prostate specific antigen
(PSA) and transrectal ultrasonography (TRUS) in the detection of prostate cancer. Final
diagnoses confirmed histopatholgically by TRUS-guided needle biopsy resulted in 31
prostate cancers. The prostate cancer detection rates by DRE, PSA (>2.5 ng/§¢) and
TRUS were 47.5%, 34.1% and 48.1%, respectively. Sensitivity and specificity of DRE,
TRUS and serum PSA were 90%, °ú0%, 81%, 42.9% and 100%, 14.3% respectively.
Especially PSA had too low specificity in discrimination of malignant diseases from the
benign. Three out of 31 patients with prostate cancer showed only one abnormal
findings from three items. Patients with abnormal findings in DRE-PSA, TRUS-PSA
and DRE-TRUS stowed the detection rates of cancer 57.1%, 14.3% and 62.5%
respectively. The detection rate was highest as 73.5% when Patients showed amino¡¸mal
findings in all three items.
Our results suggest that the combination of DRE, TRUS and serum PSA increased
the detection rate of cancer but several points such as cost-effectiveness and efforts to
increase specificity methodologically should be taken into consideration before we apply
those diagnostic modalities to screening of prostate cancers as routine procedures.

Å°¿öµå

Prostate cancer; Digital rectal examination; Prostate specific antigen;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS